U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C17H21NO2
Molecular Weight 271.3541
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of NISOXETINE

SMILES

CNCCC(OC1=C(OC)C=CC=C1)C2=CC=CC=C2

InChI

InChIKey=ITJNARMNRKSWTA-UHFFFAOYSA-N
InChI=1S/C17H21NO2/c1-18-13-12-15(14-8-4-3-5-9-14)20-17-11-7-6-10-16(17)19-2/h3-11,15,18H,12-13H2,1-2H3

HIDE SMILES / InChI

Molecular Formula C17H21NO2
Molecular Weight 271.3541
Charge 0
Count
Stereochemistry RACEMIC
Additional Stereochemistry No
Defined Stereocenters 0 / 1
E/Z Centers 0
Optical Activity ( + / - )

Nisoxetine, 3-(o-methoxyphenoxy)-3-phenyl-N-methyl-propyl-amine, is a most active and selective inhibitor of norepinephrine uptake, which was developed by Eli Lilly as an antidepressant drug. It was shown that nisoxetine dose-dependently reduced acute food intake and the additive effect of it was preserved in obese mice. In addition, was revealed that nisoxetine produced local but not systemic analgesia against cutaneous nociceptive stimuli in rodents. However, this drug has no clinical applications in humans.

CNS Activity

Curator's Comment: Known to be CNS penetrant in rat. Human data not available

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Target ID: P23975
Gene ID: 6530.0
Gene Symbol: SLC6A2
Target Organism: Homo sapiens (Human)
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown

Approved Use

Unknown
PubMed

PubMed

TitleDatePubMed
Monoaminergic mechanisms and experimental cataplexy.
1981 Oct
Effects of chronic treatment with antidepressants on aggressiveness induced by clonidine in mice.
1982
Regulation of the human norepinephrine transporter by cocaine and amphetamine.
2000 Dec
Tyr-95 and Ile-172 in transmembrane segments 1 and 3 of human serotonin transporters interact to establish high affinity recognition of antidepressants.
2006 Jan 27
Noradrenergic mechanisms in cocaine-induced reinstatement of drug seeking in squirrel monkeys.
2007 Aug

Sample Use Guides

In Vivo Use Guide
Placebo and nisoxetine (10-20 mg b.d. for 7 days) were administered to normal volunteers in a single-bind crossover study. Adverse side effects were minimal. There were no significant changes in heart rate or blood pressure seen when no other drugs were given. The effect of nisoxetine on uptake of biogenic amines was utilized to study its mechanism of action.
Route of Administration: Oral
In Vitro Use Guide
It was investigated the interaction of nisoxetine with the human norepinephrine transporter by examining the binding of this ligand to the placental brush border membranes. Scatchard analysis revealed that nisoxetine bound with high affinity to a single class of binding sites in the membranes (dissociation constant = 13.8 +/- 0.4 nM). This value obtained from equilibrium experiments matched the value (11.2 nM) which was calculated using the association and dissociation rate constants. The maximal binding capacity (Bmax) was 5.1 +/- 0.1 pmol/mg of protein. The binding exhibited an absolute requirement for Na+ as well as Cl-. Presence of these ions enhanced the binding affinity without affecting Bmax. Kinetic analyses revealed that the coupling ratio of Na+/nisoxetine was 2, whereas the coupling ratio of Cl-/nisoxetine was 1.
Substance Class Chemical
Created
by admin
on Fri Dec 15 16:12:57 UTC 2023
Edited
by admin
on Fri Dec 15 16:12:57 UTC 2023
Record UNII
17NV064B2D
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
NISOXETINE
INN   USAN  
INN   USAN  
Official Name English
(±)-3-(O-METHOXYPHENOXY)-N-METHYL-3-PHENYLPROPYLAMINE
Common Name English
nisoxetine [INN]
Common Name English
COMPOUND 89218
Code English
NISOXETINE [USAN]
Common Name English
COMPOUND-89218
Code English
BENZENEPROPANAMINE, .GAMMA.-(2-METHOXYPHENOXY)-N-METHYL-, (±)-
Systematic Name English
NSC-283481
Code English
Classification Tree Code System Code
NCI_THESAURUS C265
Created by admin on Fri Dec 15 16:12:58 UTC 2023 , Edited by admin on Fri Dec 15 16:12:58 UTC 2023
Code System Code Type Description
CAS
53179-07-0
Created by admin on Fri Dec 15 16:12:57 UTC 2023 , Edited by admin on Fri Dec 15 16:12:57 UTC 2023
PRIMARY
CHEBI
73410
Created by admin on Fri Dec 15 16:12:57 UTC 2023 , Edited by admin on Fri Dec 15 16:12:57 UTC 2023
PRIMARY
EPA CompTox
DTXSID0045175
Created by admin on Fri Dec 15 16:12:57 UTC 2023 , Edited by admin on Fri Dec 15 16:12:57 UTC 2023
PRIMARY
NCI_THESAURUS
C75172
Created by admin on Fri Dec 15 16:12:58 UTC 2023 , Edited by admin on Fri Dec 15 16:12:58 UTC 2023
PRIMARY
INN
3878
Created by admin on Fri Dec 15 16:12:58 UTC 2023 , Edited by admin on Fri Dec 15 16:12:58 UTC 2023
PRIMARY
DRUG BANK
DB09186
Created by admin on Fri Dec 15 16:12:57 UTC 2023 , Edited by admin on Fri Dec 15 16:12:57 UTC 2023
PRIMARY
MESH
C011386
Created by admin on Fri Dec 15 16:12:58 UTC 2023 , Edited by admin on Fri Dec 15 16:12:58 UTC 2023
PRIMARY
PUBCHEM
4500
Created by admin on Fri Dec 15 16:12:58 UTC 2023 , Edited by admin on Fri Dec 15 16:12:58 UTC 2023
PRIMARY
SMS_ID
100000083909
Created by admin on Fri Dec 15 16:12:58 UTC 2023 , Edited by admin on Fri Dec 15 16:12:58 UTC 2023
PRIMARY
ChEMBL
CHEMBL295467
Created by admin on Fri Dec 15 16:12:57 UTC 2023 , Edited by admin on Fri Dec 15 16:12:57 UTC 2023
PRIMARY
EVMPD
SUB09308MIG
Created by admin on Fri Dec 15 16:12:57 UTC 2023 , Edited by admin on Fri Dec 15 16:12:57 UTC 2023
PRIMARY
WIKIPEDIA
NISOXETINE
Created by admin on Fri Dec 15 16:12:58 UTC 2023 , Edited by admin on Fri Dec 15 16:12:58 UTC 2023
PRIMARY
NSC
283481
Created by admin on Fri Dec 15 16:12:58 UTC 2023 , Edited by admin on Fri Dec 15 16:12:58 UTC 2023
PRIMARY
FDA UNII
17NV064B2D
Created by admin on Fri Dec 15 16:12:57 UTC 2023 , Edited by admin on Fri Dec 15 16:12:57 UTC 2023
PRIMARY
Related Record Type Details
LABELED -> NON-LABELED
Related Record Type Details
ACTIVE MOIETY